Menu

States could face more pressure to enact laws prohibiting drugmaker 340B claims data requirements after Eli Lilly began to cut off 340B pricing from covered entities that failed to comply with its in-house claims data policy.

Lilly’s In-House Data Policy Enforcement Could Trigger New State Legislative Activity

June 18, 2026 Luke Zarzecki, National Correspondent 340B Report Views

State 340B legislative activity could heat up again as providers look for protections from the growing number of manufacturer claims [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

If you are not yet a paid subscriber, please Subscribe now

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Luke Zarzecki

New Vermont Law Repeals 340B Rebate Ban, Expands Data Reporting Protections

What New HRSA Documents Reveal About Its Future 340B Rebate Plans